Immune-related adverse events induced by programmed death protein-1 inhibitors from the perspective of lymphoma immunotherapy  

作　　者：Yong-Zhe Hou Qin Zhang Hai Bai Tao Wu Ya-Jie Chen 

机构地区：[1]Department of Hematology,Center of Hematologic Diseases of Chinese PLA,The 940th Hospital of Joint Logistics Support force of Chinese People's Liberation Army,Lanzhou 730050,Gansu Province,China [2]Department of First Clinical Medical College,Gansu University of Chinese Medicine,Lanzhou 730030,Gansu Province,China [3]Key Laboratory of Stem Cells and Gene Drugs of Gansu Province,Lanzhou 730050,Gansu Province,China

出　　处：《World Journal of Clinical Cases》2023年第7期1458-1466,共9页世界临床病例杂志

基　　金：the 2022 Project of Innovation Foundation of Outstanding Graduate Students of Gansu Province;the Graduate Innovation Foundation of Major Project of Education Department of Gansu Province,No.lccx2021001;the Gansu Provincial Science and Technology Plan Project Assignment(Innovation Base and Talent Plan),No.21JR7RA013;the Gansu Province Innovation Base and Talent Plan(Gansu Province Leukemia Clinical Research Center),No.21JR7RA015;the 2022 Hospital Project of The 940th Hospital of Joint Logistics Support Force of Chinese People's Liberation Army,No.2022yxky015.

摘　　要：Lymphoma,which is highly malignant,stems from lymph nodes and lymphoid tissue.Lymphoma cells express programmed death-ligand 1/2(PD-L1/PD-L2),which binds with programmed cell death 1 protein(PD-1)to establish inhibitory signaling that impedes the normal function of T cells and allows tumor cells to escape immune system surveillance.Recently,immune checkpoint inhibitor immunotherapies such as PD-1 inhibitors(nivolumab and pembrolizumab)have been introduced into the lymphoma treatment algorithm and have shown remarkable clinical efficacy and greatly improve prognosis in lymphoma patients.Accordingly,the number of lymphoma patients who are seeking treatment with PD-1 inhibitors is growing annually,which results in an increasing number of patients developing immune-related adverse events(irAEs).The occurrence of irAEs inevitably affects the benefits provided by immunotherapy,particularly when PD-1 inhibitors are applied.However,the mechanisms and characteristics of irAEs induced by PD-1 inhibitors in lymphoma need further investigation.This review article summarizes the latest research advances in irAEs during treatment of lymphoma with PD-1 inhibitors.A comprehensive understanding of irAEs incurred in immunotherapy can help to achieve better efficacy with PD-1 inhibitors in lymphoma.

关 键 词：LYMPHOMA Programmed cell death 1 receptor Immune checkpoint inhibitors Immune-related adverse events Nivolumab Pembrolizumab 

分 类 号：R733[医药卫生—肿瘤]